Neurodegenerative disease
MONDO:0005559A disorder of the central nervous system characterized by gradual and progressive loss of neural tissue and neurologic function.
Also known as: degenerative disease, brain degeneration, central nervous system degenerative disorder, central nervous system neurodegenerative disorder, degenerative disorder of central nervous system, cerebral degeneration disease
3277 clinical trials for this condition and its sub-types, 186 tagged with Neurodegenerative disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neurodegenerative disease
-
Tauopathy 24 trials · 1,190 incl. sub-types
2 sub-types
- Alzheimer disease 1,184 trials Sub-types →
- Argyrophilic grain disease 0 trials
-
Demyelinating disease 27 trials · 931 incl. sub-types
8 sub-types
- Demyelinating disease of central nervous system 4 trials · 860 incl. sub-types Sub-types →
- Polyradiculoneuropathy 1 trial · 64 incl. sub-types Sub-types →
- Demyelinating polyneuropathy 2 trials · 62 incl. sub-types Sub-types →
- Acute disseminated encephalomyelitis 7 trials · 8 incl. sub-types Sub-types →
- Central pontine myelinolysis 2 trials
- Balo concentric sclerosis 0 trials
- Schilder disease 0 trials
- Boylan dew greco syndrome 0 trials
-
Inherited neurodegenerative disorder 10 trials · 807 incl. sub-types
82 sub-types
- Frontotemporal dementia 132 trials · 178 incl. sub-types Sub-types →
- Hereditary motor neuron disease 1 trial · 169 incl. sub-types Sub-types →
- Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types Sub-types →
- Huntington disease and related disorders 0 trials · 91 incl. sub-types Sub-types →
- Progressive supranuclear palsy 73 trials · 77 incl. sub-types Sub-types →
- Leukodystrophy 6 trials · 72 incl. sub-types Sub-types →
- Familial Alzheimer disease 13 trials · 55 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 27 trials · 33 incl. sub-types Sub-types →
- Hereditary optic atrophy 6 trials · 23 incl. sub-types Sub-types →
- Neuronal ceroid lipofuscinosis 6 trials · 23 incl. sub-types Sub-types →
- GM2 gangliosidosis 14 trials · 19 incl. sub-types Sub-types →
- Kennedy disease 19 trials
- Corticobasal syndrome 19 trials
- Frontotemporal dementia with motor neuron disease 13 trials · 19 incl. sub-types Sub-types →
- Posterior cortical atrophy 11 trials
- Chediak-Higashi syndrome 9 trials
- Neurodegeneration with brain iron accumulation 1 trial · 8 incl. sub-types Sub-types →
- APP-related brain and vascular amyloidosis 0 trials · 5 incl. sub-types Sub-types →
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 0 trials · 5 incl. sub-types Sub-types →
- Inherited Creutzfeldt-Jakob disease 5 trials
- TUBB4A-related neurologic disorder 4 trials Sub-types →
- Fatal familial insomnia 4 trials
- Mitochondrial DNA depletion syndrome 4a 3 trials
- Alzheimer disease 17 1 trial
- Alzheimer disease 18 1 trial
- Ataxia-telangiectasia-like disorder 1 trial Sub-types →
- Developmental and epileptic encephalopathy, 35 1 trial
- Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures 1 trial
- Neurodegenerative syndrome due to cerebral folate transport deficiency 1 trial
- Neuronal intranuclear inclusion disease 1 trial
- Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome 1 trial
- DCTN1-related neurodegeneration 0 trials Sub-types →
- Huntington disease-like 1 0 trials
- Huntington disease-like 2 0 trials
- ITM2B amyloidosis 0 trials Sub-types →
- PEHO syndrome 0 trials
- PRKAR1B-related neurodegenerative dementia with intermediate filaments 0 trials
- X-linked neurodegenerative syndrome, Bertini type 0 trials
- X-linked neurodegenerative syndrome, Hamel type 0 trials
- Agenesis of the corpus callosum with peripheral neuropathy 0 trials
- Amyotrophic lateral sclerosis-parkinsonism-dementia complex 0 trials
- Angioid streaks of choroid 0 trials
- Attenuated Chédiak-Higashi syndrome 0 trials
- Autosomal recessive cerebral atrophy 0 trials
- Boylan dew greco syndrome 0 trials
- Cerebellar ataxia-hypogonadism syndrome 0 trials Sub-types →
- Cerebral sclerosis similar to Pelizaeus-Merzbacher disease 0 trials
- Combined oxidative phosphorylation deficiency 29 0 trials
- Deafness dystonia syndrome 0 trials
- Diffuse cerebral and cerebellar atrophy - intractable seizures - progressive microcephaly syndrome 0 trials
- Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities 0 trials
- Early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy 0 trials
- Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome 0 trials
- Encephalopathy due to beta-mercaptolactate-cysteine disulfiduria 0 trials
- Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy 0 trials Sub-types →
- Facial onset sensory and motor neuronopathy 0 trials
- Fatal post-viral neurodegenerative disorder 0 trials
- Ferro-cerebro-cutaneous syndrome 0 trials
- Hereditary sensory neuropathy-deafness-dementia syndrome 0 trials
- Hypotonia, infantile, with psychomotor retardation and characteristic facies 0 trials Sub-types →
- Infantile cerebellar-retinal degeneration 0 trials
- Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 0 trials
- Microphthalmia-brain atrophy syndrome 0 trials
- Myoclonic cerebellar dyssynergia 0 trials
- Neurodegeneration and seizures due to copper transport defect 0 trials
- Neurodegeneration with ataxia and late-onset optic atrophy 0 trials
- Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset 0 trials
- Neurodegeneration with developmental delay, early respiratory failure, myoclonic seizures, and brain abnormalities 0 trials
- Neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline 0 trials
- Neurodegeneration, childhood-onset, with cerebellar ataxia and cognitive decline 0 trials
- Neurodegeneration, childhood-onset, with cerebellar atrophy 0 trials
- Neurodegeneration, childhood-onset, with hypotonia, respiratory insufficiency, and brain imaging abnormalities 0 trials
- Neurodegeneration, childhood-onset, with multisystem involvement due to mitochondrial dysfunction 0 trials
- Neurodegeneration, childhood-onset, with progressive microcephaly 0 trials
- Neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia 0 trials
- Neurodegeneration, infantile-onset, biotin-responsive 0 trials
- Neurodegenerative disorder with cerebellar and caudate atrophy 0 trials
- Neurodegenerative disorder, X-linked, female-restricted, with parkinsonism and cognitive impairment 0 trials
- Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome 0 trials
- Radiation sensitivity/chromosome instability syndrome, autosomal dominant 0 trials
- Severe neurodegenerative syndrome with lipodystrophy 0 trials
- Striatonigral degeneration 0 trials Sub-types →
-
Motor neuron disorder 69 trials · 506 incl. sub-types
4 sub-types
- Amyotrophic lateral sclerosis 327 trials · 341 incl. sub-types Sub-types →
- Hereditary motor neuron disease 1 trial · 169 incl. sub-types Sub-types →
- Acquired motor neuron disease 0 trials · 39 incl. sub-types Sub-types →
- Madras motor neuron disease 0 trials
-
Synucleinopathy 18 trials · 237 incl. sub-types
2 sub-types
- Lewy body dementia 130 trials
- Multiple system atrophy 110 trials · 119 incl. sub-types Sub-types →
-
Cerebellar degeneration 6 trials · 150 incl. sub-types
2 sub-types
- Cerebellar ataxia 40 trials · 144 incl. sub-types Sub-types →
- Paraneoplastic cerebellar degeneration 1 trial
-
Primary progressive aphasia 42 trials · 71 incl. sub-types
2 sub-types
- GRN-related frontotemporal lobar degeneration with Tdp43 inclusions 6 trials · 47 incl. sub-types Sub-types →
- Logopenic progressive aphasia 15 trials
-
Cerebral degeneration 0 trials · 61 incl. sub-types
2 sub-types
- Pick disease 35 trials
- Corticobasal degeneration disorder 28 trials
-
Secondary Parkinson disease 9 trials
1 sub-type
- Postencephalitic Parkinson disease 0 trials
-
Neuroaxonal dystrophy 1 trial · 9 incl. sub-types
2 sub-types
- Neurodegeneration with brain iron accumulation 1 trial · 8 incl. sub-types Sub-types →
- Neuroaxonal dystrophy renal tubular acidosis 0 trials
-
Marchiafava-Bignami disease 1 trial
-
Human prion disease 1 trial
4 sub-types
- Acquired human prion disease 0 trials
- Kuru 0 trials
- Sporadic fatal insomnia 0 trials
- Variably protease-sensitive prionopathy 0 trials
-
Brachial amyotrophic diplegia 0 trials
-
Choroidal sclerosis 0 trials
4 sub-types
- Angioid streaks of choroid 0 trials
- Diffuse secondary choroid atrophy 0 trials
- Hereditary choroidal atrophy 0 trials Sub-types →
- Senile atrophy of choroid 0 trials
-
Eyelid degenerative disorder 0 trials
-
Hypertrophic olivary degeneration 0 trials
-
2 sub-types
-
Olivopontocerebellar atrophy 0 trials
-
Primary progressive freezing gait 0 trials
-
Senile degeneration of brain 0 trials
-
Superficial siderosis 0 trials
Most studied deeper sub-types
-
Can mindfulness help caregivers stay healthy? new study tests a brief program
Disease control CompletedThis study tests a short mindfulness and lifestyle program for people caring for loved ones with neurodegenerative diseases like Alzheimer's or Parkinson's. Caregivers often neglect their own health, raising their risk for heart disease and early death. The program combines in-pe…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug targets brain inflammation to slow Alzheimer's
Disease control CompletedThis study tested an experimental drug called XPro1595 in 208 people with early Alzheimer's disease who also had signs of brain inflammation. The goal was to see if the drug could improve memory, thinking, and daily function compared to a placebo over 24 weeks. Researchers also c…
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Huntington's drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested a drug called PTC518 in 159 adults with Huntington's disease to see if it is safe and can lower a harmful protein in the blood. Participants received different doses of the drug or a placebo for up to 12 months. The goal is to slow disease progression by targeti…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an Immune-Modulating drug slow early Alzheimer's?
Disease control CompletedThis phase 2 trial investigates whether lenalidomide, a drug that calms inflammation, can slow cognitive decline in people with mild cognitive impairment due to Alzheimer's disease. Participants take lenalidomide or a placebo for up to 12 months, followed by a 6-month washout per…
Phase 2 • Sponsor: St. Joseph's Hospital and Medical Center, Phoenix • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Can a failed ALS drug help PSP patients? new trial results are in
Disease control CompletedThis completed Phase 2b/3 trial tested the drug AMX0035 in 139 people with progressive supranuclear palsy (PSP), a rare brain disease that causes problems with balance, movement, and thinking. The study compared the drug to a placebo to see if it could slow the disease. The resul…
Phase 2/3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Gene therapy shows promise in Long-Term study for rare blindness
Disease control CompletedThis study followed 62 people with Leber Hereditary Optic Neuropathy (LHON), a rare inherited eye disease that causes vision loss, for up to 5 years after they received a single gene therapy treatment called GS010. The goal was to see if the treatment remained safe and if any vis…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Gene therapy injection shows promise for rare eye disease
Disease control CompletedThis phase 3 trial tested a single injection of GS010 gene therapy in 39 people with Leber Hereditary Optic Neuropathy (LHON) who had vision loss for 6 months or less. The treatment aims to improve vision by delivering a working copy of the ND4 gene to the eye. Results measured c…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy shows promise for rare eye disease causing blindness
Disease control CompletedThis study tested a one-time gene therapy injection, GS010, in 37 adults with Leber Hereditary Optic Neuropathy (LHON), a genetic condition that causes rapid vision loss. Participants had vision loss for 6 to 12 months before treatment. The goal was to see if the therapy could im…
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug PGN-EDODM1 tested for muscle disease
Disease control CompletedThis early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.
Phase 1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Parkinson's drug shows promise in Year-Long trial
Disease control CompletedThis study tested the safety and effectiveness of tavapadon, an experimental drug, in 992 people with Parkinson's disease over 58 weeks. Participants took flexible doses of the medication to see how well it controlled symptoms and what side effects occurred. The goal was to under…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug tavapadon tested to ease Parkinson's symptoms
Disease control CompletedThis Phase 3 trial tested whether tavapadon, a daily pill, can improve movement and daily activities in people with early Parkinson's disease. Over 300 participants took either tavapadon or a placebo for 27 weeks. The study measured changes in motor function and daily living skil…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for ALS patients: experimental drug IFB-088 tested in trial
Disease control CompletedThis phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months.…
Phase 2 • Sponsor: InFlectis BioScience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New Parkinson's drug HER-096 passes first safety check in small trial
Disease control CompletedThis early-stage trial tested the safety of a new drug called HER-096 for Parkinson's disease. It involved 32 people: healthy volunteers who got a single dose, and Parkinson's patients who received multiple doses over four weeks. The main goal was to check for side effects and ho…
Phase 1 • Sponsor: Herantis Pharma Plc. • Aim: Disease control
Last updated Jun 26, 2026 16:31 UTC
-
Can a tablet replace the Doctor's office for memory tests?
Diagnosis CompletedThis study tested a tablet-based platform called Tenèpsia® for remote cognitive assessments in 250 healthy adults and people with cognitive impairment. The goal was to collect normal test scores and validate the digital tool for diagnosing neurocognitive disorders. If proven reli…
Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Simple blood test could spot Alzheimer's early
Diagnosis CompletedThis study tested a new blood test that uses a microfluidic chip to detect Alzheimer's disease. Researchers collected blood and urine samples from 150 people, including those with Alzheimer's, other brain diseases, and healthy volunteers. The goal was to see if the test could acc…
Sponsor: Amoneta Diagnostics SAS • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Simple blood test could spot Alzheimer's early
Diagnosis CompletedThis study is working on a blood test to help diagnose Alzheimer's disease. Researchers are measuring two specific markers in the blood of 200 people—some with Alzheimer's and some healthy—to see if these markers can reliably tell the difference. The goal is to create a simple, n…
Sponsor: Amoneta Diagnostics SAS • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Ultrasound may spot rare nerve disease CANVAS
Diagnosis CompletedThis study tested whether ultrasound of the nerves can help diagnose CANVAS, a rare genetic disorder that causes balance problems, nerve damage, and dizziness. Researchers measured nerve size in 35 people with confirmed CANVAS and compared them to healthy individuals. The goal wa…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
AI eye scan could diagnose brain diseases in seconds
Diagnosis CompletedResearchers tested an artificial intelligence program that analyzes retinal images to diagnose several nerve and brain conditions, such as optic neuropathy and brain tumors. The study used data from 693 patients with confirmed diagnoses. The goal is to create a fast triage tool f…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Diagnosis
Last updated Jun 26, 2026 14:30 UTC
-
Harp melodies may tame Dementia's sundowning storm
Symptom relief CompletedThis study tests whether weekly live harp music sessions can reduce behavioral symptoms like agitation and anxiety in nursing home residents with moderate-to-severe dementia. Participants in memory care units will listen to a harp therapist play during the late afternoon, a time …
Sponsor: LNA SANTE • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Video therapy may help Parkinson's patients walk better
Symptom relief CompletedThis study tested whether adding action observation therapy (watching videos of movements) to standard physical therapy could help people with Parkinson's disease who experience freezing of gait. 42 participants aged 50-80 completed the trial. The goal was to see if this approach…
Sponsor: University of Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a personalized support program ease the burden of MSA?
Symptom relief CompletedThis study tested a personalized counseling and support program for 130 people with multiple system atrophy (MSA) and their caregivers. The program aimed to identify individual needs and improve daily life management. Researchers measured quality of life and depression symptoms t…
Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Robot caregiver? AI assistant tested for dementia patients at home
Symptom relief CompletedThis study tested a software system that uses a humanoid robot to give cognitive and motor tests to people with early Alzheimer's or other mild to moderate dementia. The goal was to see if the robot could effectively administer tests like the Mini Mental State Exam (MMSE) and hel…
Sponsor: IRCCS Centro Neurolesi Bonino Pulejo • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Parkinson's patients try antioxidant supplements to boost brain health
Symptom relief CompletedThis study looked at whether nutritional supplements, specifically N-acetyl cysteine (NAC) given orally and intravenously, could support brain function in people with Parkinson's disease. The researchers measured dopamine activity and markers of inflammation in the brain using sp…
Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Could a smart car fix your walk? new study tests electric vehicle for Parkinson's and dementia
Symptom relief CompletedThis completed study tested a smart electric vehicle designed to detect and improve walking problems in 120 people aged 60-85 with Parkinson's disease or dementia. The vehicle uses artificial intelligence to monitor gait, provide feedback, and assist with balance. The main goal w…
Sponsor: Taipei Medical University Shuang Ho Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Gene therapy injection tested for ALS safety
Symptom relief CompletedThis early-phase trial tested whether a gene therapy called VM202 is safe when injected into muscles of 18 people with ALS. The study focused on side effects over 9 months, not on whether the treatment improves symptoms. All participants had ALS for less than 2 years and had at l…
Phase 1/2 • Sponsor: Helixmith Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
High-Intensity workouts show promise for Parkinson's patients
Symptom relief CompletedThis study tested whether a high-intensity functional training (HIFT) program could improve both thinking and physical abilities in people with Parkinson's disease. Fifteen participants with early-stage Parkinson's completed the program, which included strength and coordination e…
Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 26, 2026 14:52 UTC
-
New imaging database aims to sharpen Parkinson's diagnosis
Knowledge-focused CompletedThis completed study created the first international database of Datscan imaging values from 300 patients. The goal was to help doctors better diagnose Parkinson's disease and other neurodegenerative conditions by comparing brain scan results. Researchers hope this database will …
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Dementia care: the hidden struggles of extended family caregivers revealed
Knowledge-focused CompletedThis completed study looked at the experiences of 275 extended family members (like grandchildren, siblings, and nieces/nephews) who care for a person with dementia. Researchers interviewed caregivers about their daily tasks, stress, and use of support services. The goal is to us…
Sponsor: Karen Roberto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brain-Computer device nears market for Non-Verbal patients
Knowledge-focused CompletedThis study tested whether a brain-computer interface (BCI) device is ready for commercial use to help people with minimal movement communicate. Researchers worked with 8 device users, plus speech therapists and support staff, to evaluate how well the device worked at home. The go…
Sponsor: Kendrea Garand • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for dementia genes in 2,256-Person study
Knowledge-focused CompletedThis study collected blood samples from over 2,200 people with Alzheimer's or other dementias, plus healthy volunteers, to search for genes linked to these diseases. Researchers aimed to identify new genetic causes and better understand how genes affect disease risk and progressi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Smart homes for seniors: telemonitoring trial aims to cut hospital stays
Knowledge-focused CompletedThis study tested whether home automation and remote monitoring can help elderly people (65+) with multiple chronic conditions live safely at home. Over 500 participants had their homes equipped with sensors that tracked health signs and sent alerts to doctors. The main goal was …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
NAD+ pill trial: will it sharpen aging brains?
Knowledge-focused CompletedThis study tested whether a daily NAD+ supplement can improve thinking and reduce inflammation in healthy women aged 40 to 80. Participants took either NAD+ or a placebo for 4 weeks and completed computer tests and blood draws. The goal was to see if NAD+ affects memory, attentio…
Sponsor: University of Rhode Island • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New study tracks daily life impact of rare eye disease
Knowledge-focused CompletedThis study looked at 44 people with a rare inherited eye condition called Leber Hereditary Optic Neuropathy (LHON) that causes vision loss. Researchers reviewed medical records and asked participants about their vision, health, and quality of life. The goal was to better understa…
Sponsor: GenSight Biologics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Italian swallowing assessment tool validated for neurodegenerative patients
Knowledge-focused CompletedThis study aimed to translate and validate an Italian version of a tool that helps speech therapists assess swallowing difficulties (dysphagia) in people with neurodegenerative diseases like Parkinson's or ALS. Researchers tested the tool on 101 adults with such conditions to ens…
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Obesity may weaken gut and brain barriers, study finds
Knowledge-focused CompletedThis observational study looked at how obesity affects the gut barrier and the blood-brain barrier—two systems that protect the body and brain. Researchers compared 25 people with obesity to 25 healthy individuals, using MRI scans, sugar tests, and cognitive assessments. The goal…
Sponsor: University Hospital, Gentofte, Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Brain scans and memory tests shed light on how the brain works after injury
Knowledge-focused CompletedThis completed study looked at how different types of brain damage—from strokes, tumors, infections, or degenerative diseases—affect thinking and memory. Researchers used brain scans (MRI) and cognitive tests in 346 patients and healthy volunteers to map which brain areas are res…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Healthy volunteers test new drug for brain disease clues
Knowledge-focused CompletedThis early-stage study tested the safety of a drug called GV1001 in 59 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was to see if the drug is safe and how the body processes it, not to treat any disease. Results w…
Phase 1 • Sponsor: GemVax & Kael • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC